[1]陈妹妹,梁瑜祯,李争明,等.利拉鲁肽对白色脂肪的作用[J].国际内分泌代谢杂志,2020,40(05):331-334.[doi:10.3760/cma.j.cn121383-20191206-12014]
　Chen Meimei,Liang Yuzhen,Li Zhengming,et al.Effect of liraglutide on white fat[J].International Journal of Endocrinology and Metabolism,2020,40(05):331-334.[doi:10.3760/cma.j.cn121383-20191206-12014]
点击复制

利拉鲁肽对白色脂肪的作用()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
40
期数:
2020年05期
页码:
331-334
栏目:
综述
出版日期:
2020-09-20

文章信息/Info

Title:
Effect of liraglutide on white fat
作者:
陈妹妹1; 梁瑜祯2; 李争明2; 夏宁1
1广西医科大学第一附属医院内分泌科,南宁 530021; 2广西医科大学第二附属医院内分泌科,南宁 530007
Author(s):
Chen Meimei1;  Liang Yuzhen2;  Li Zhengming2;  Xia Ning1
1Department of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China; 2Department of Endocrinology, The Second Affiliated Hospital of Guangxi Medical University, Nanning 530007, China
关键词:
利拉鲁肽;  白色脂肪;  白色脂肪棕色化
Keywords:
Liraglutide;  White fat;  Browning of white fat
DOI:
10.3760/cma.j.cn121383-20191206-12014
文献标志码:
A
摘要:
大量研究发现,减少白色脂肪,促进白色脂肪棕色化可以对抗肥胖及其共患病。利拉鲁肽作为一种新型降糖药及减重药,具有降脂减重的作用。然而在动物实验和人体研究中,利拉鲁肽对血脂的作用不尽一致,且其在白色脂肪及白色脂肪棕色化中的机制尚未得到阐释。因此,利拉鲁肽对白色脂肪的作用及其可能机制需要更深入的研究,旨在更好的探索利拉鲁肽的减重机制。
Abstract:
A large number of studies have found that reducing white fat and promoting the browning of white fat can fight against obesity and its comorbidities. As a new type of hypoglycemic and weight-loss drug, liraglutide has the effect of reducing blood fat and weight. However, in animal experiments and human studies, the effect of liraglutide on blood lipids is not consistent, and its mechanism in the browning of white fat and white fat has not been explained. Therefore, the effect of liraglutide on white fat and its possible mechanism need more in-depth study in order to better explore the mechanism of weight loss of liraglutide.

参考文献/References:

[1] Poher AL, Altirriba J, Veyrat-Durebex C, et al. Brown adipose tissue activity as a target for the treatment of obesity/insulin resistance[J].Front Physiol,2015,6:4.DOI:10.3389/fphys.2015.00004.
[2] Cereijo R,Giralt M.Thermogenic brown and beige/brite adipogenesis in humans[J].Ann Med,2015,47(2):169-177.DOI: 10.3109/07853890.2014.952328.
[3] Nuffer WA, Trujillo JM. Liraglutide:a new option for the treatment of obesity[J]. Pharmacotherapy, 2015, 35(10):926-934.DOI:10.1002/phar.1639.
[4] Chen Y, Pan R, Pfeifer A. Fat tissues, the brite and the dark sides[J].Pflugers Arch, 2016, 468(11-12):1803-1807.DOI:10.1007/s00424-016-1884-8.
[5] Scheja L.The endocrine function of adipose tissues in health and cardiometabolic disease[J].Nat Rev Endocrinol,2019,15(9):507-524.DOI: 10.1038/s41574-019-0230-6.
[6] Shen H,Jiang L,Lin JD,et al.Brown fat activation mitigates alcohol-induced liver steatosis and injury in mice[J].J Clin Invest,2019,129(6):2305-2317.DOI:10.1172/JCI124376.
[7] Froy O.The circadian clock in white and brown adipose tissue: mechanistic, endocrine, and clinical aspects[J].Endocr Rev,2018,39(3):261-273.DOI:10.1210/er.2017-00193.
[8] Rui L.Brown and beige adipose tissues in health and disease[J].Compr Physiol,2017,7(4):1281-1306.DOI: 10.1002/cphy.c170001.
[9] Lasar D,Julius A,Fromme T.Browning attenuates murine white adipose tissue expansion during postnatal development[J].Biochim Biophys Acta,2013,1831(5):960-968.DOI:10.1016/j.bbalip.2013.01.016.
[10] White JD,Dewal RS.The beneficial effects of brown adipose tissue transplantation[J].Mol Aspects Med,2019,68:74-81.DOI:10.1016/j.mam.2019.06.004.
[11] Russell-Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue[J].Mol Cell Endocrinol, 2009, 297(1):137-140.DOI:10.1016/j.mce.2008.11.018.
[12] Drucker DJ. The biology of incretin hormones[J].Cell Metab, 2006,3(3):153-165.DOI:10.1016/j.cmet.2006.01.004.
[13] Liang Y, Li Z, Liang S, et al. Hepatic adenylate cyclase 3 is upregulated by Liraglutide and subsequently plays a protective role in insulin resistance and obesity[J].Nutr Diabetes, 2016,6(1):e191.DOI:10.1038/nutd.2015.37.
[14] Li Z, Liang Y, Xia N, et al. Liraglutide reduces body weight by upregulation of adenylate cyclase 3[J].Nutr Diabetes,2017,7(5):e265.DOI:10.1038/nutd.2017.17.
[15] Madsen MSA,Holm JB,Pallejà A,et al.Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice[J].Sci Rep,2019,9(1):15582.DOI:10.1038/s41598-019-52103-x.
[16] Yang SH, Xu RX, Cui CJ, et al. Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism[J].Cardiovasc Diabetol, 2018, 17(1):48.DOI:10.1186/s12933-018-0689-9.
[17] Wu YR, Shi XY, Yan C,et al. Liraglutide improves lipid metabolism by enhancing cholesterol efux associated with ABCA1 and ERK1/2 pathway[J].Cardiovasc Diabetol,2019,18(1):146.DOI:10.1186/s12933-019-0954-6.
[18] Niina M, Sanni S, Elias B, et al. Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes:a single-centre randomised controlled study[J].Diabetes Obes Metab,2019,21(1):84-94.DOI:10.1111/dom.13487.
[19] Chen XM, Zhang WQ, Tian Y,et al. Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes[J].Cardiovasc Diabetol,2018,17(1):53. DOI:10.1186/s12933-018-0701-4.
[20] Peradze N, Farr OM,Perakakis N,et al.Short-term treatment with high dose liraglutide improves lipid and lipoprotein profle and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus:a randomized, placebo-controlled,cross-over,double-blind clinical trial[J].Cardiovasc Diabetol,2019,18(1):141.DOI:10.1186/s12933-019-0945-7.
[21] Bouchi R,Nakano Y,Fukuda T,et al.Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial[J].Endocr J,2017,64(3):269-281.DOI:10.1507/endocrj.EJ16-0449.
[22] Iacobellis G,Mohseni M,Bianco SD.Liraglutide causes large and rapid epicardial fat reduction[J].Obesity(Silver Spring),2017,25(2):311-316.DOI:10.1002/oby.21718.
[23] 张楠,张一,章秋,等.利拉鲁肽诱导肥胖2型糖尿病大鼠白色脂肪组织中FGF21的表达及机制[J].中国药理学通报,2018,34(6):824-830.DOI:10.3969/j.issn.1001-1978.2018.06.017.
[24] Nonogaki K,Hazama M.Liraglutide suppresses obesity and hyperglycemia associated with increases in hepatic fibroblast growth factor 21 production in KKAy mice[J].Biomed Res Int,2014,2014:751930.DOI: 10.1155/2014/751930.
[25] 栗红蕊,崔岩,王姣,等.利拉鲁肽对肥胖大鼠脂肪组织内质网应激的影响[J].中国药房,2014,25(21):1946-1948.DOI:10.6039/j.issn.1001-0408.2014.21.09.
[26] Shao Y,Yuan G,Zhang J.Liraglutide reduces lipogenetic signals in visceral adipose of db/db mice with AMPK activation and Akt suppression[J].Drug Des Devel Ther,2015,9:1177-1184.DOI: 10.2147/DDDT.S79175.
[27] Suzuki D,Toyoda M,Kimura M,et al.Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus[J].Intern Med,2013,52(10):1029-1034.DOI: 10.2169/internalmedicine.52.8961.
[28] Zhao L,Zhu C,Lu M,et al.The key role of a glucagon-like peptide-1 receptor agonist in body fat redistribution[J].J Endocrinol,2019,240(2):271-286.DOI: 10.1530/JOE-18-0374.
[29] Iacobellis G,Mohseni M,Bianco SD.Liraglutide causes large and rapid epicardial fat reduction[J].Obesity(Silver Spring),2017,25(2):311-316.DOI:10.1002/oby.21718.
[30] 吕丹,陈树春,王泽普,等.利拉鲁肽对高脂喂养大鼠脂肪组织棕色化基因表达影响的研究[J].中国糖尿病杂志,2019,27(4):300-306.DOI:10.3969/j.issn.1006-6187.2019.04.013.
[31] Zhu E,Yang Y,Zhang J,et al.Liraglutide suppresses obesity and induces brown fat-like phenotype via soluble guanylyl cyclase mediated pathway in vivo and in vitro[J].Oncotarget,2016,7(49):81077-81089.DOI: 10.18632/oncotarget.13189.
[32] 李永梅. 利拉鲁肽在脂肪细胞分化及白色脂肪棕色样变中的作用机制研究[D].天津医科大学,2018.
[33] Decara J,Rivera P,Arrabal S,et al.Cooperative role of the glucagon-like peptide-1 receptor and β3-adrenergic-mediated signalling on fat mass reduction through the downregulation of PKA/AKT/AMPK signalling in the adipose tissue and muscle of rats[J].Acta Physiol(Oxf),2018,222(4):e13008.DOI:10.1111/apha.13008.
[34] Zhou J,Poudel A,Chandramani-Shivalingappa P,et al.Liraglutide induces beige fat development and promotes mitochondrial function in diet induced obesity mice partially through AMPK-SIRT-1-PGC1-α cell signaling pathway[J].Endocrine,2019,64(2):271-283.DOI: 10.1007/s12020-018-1826-7.
[35] Lynch L,Hogan AE,Duquette D,et al.iNKT cells induce FGF21 for thermogenesis and are required for maximal weight loss in GLP1 therapy[J].Cell metab,2016,24(3):510-519.DOI: 10.1016/j.cmet.2016.08.003.
[36] 王幸. 利拉鲁肽通过下调microRNA 27b表达促进白色脂肪棕色化[D].河北医科大学,2018.

相似文献/References:

[1]刘璠,张趁儒,周慧敏,等.2型糖尿病患者利拉鲁肽替代预混胰岛素治疗的有效性和安全性分析[J].国际内分泌代谢杂志,2014,(04):237.[doi:10.3760/cma.j.issn.1673-4157.2014.04.006]
　Liu Fan,Zhang Chenru,Zhou Huimin,et al.Efficacy and safety of liraglutide switched from premixed insulin in patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2014,(05):237.[doi:10.3760/cma.j.issn.1673-4157.2014.04.006]
[2]孟旭英,范振迁,郭剑超.利拉鲁肽与格列美脲治疗2型糖尿病的系统评价[J].国际内分泌代谢杂志,2016,36(06):380.[doi:10.3760/cma.j.issn.1673-4157.2016.06.05]
　Meng Xuying,Fan Zhenqian,Guo Jianchao..Effects of liraglutide versus glimepiride for type 2 diabetes mellitus: a systematic review[J].International Journal of Endocrinology and Metabolism,2016,36(05):380.[doi:10.3760/cma.j.issn.1673-4157.2016.06.05]
[3]庄伟 王志强 王正杰 安淑华.利拉鲁肽对2型糖尿病患者血清miRNA表达及相关细胞信号通路蛋白的影响[J].国际内分泌代谢杂志,2022,42(04):307.[doi:10.3760/cma.j.cn121383-20220218-02038]
　Zhuang Wei,Wang Zhiqiang,Wang Zhengjie,et al.Effects of liraglutide on miRNAs expression profile and related cell signaling pathways in T2DM patients[J].International Journal of Endocrinology and Metabolism,2022,42(05):307.[doi:10.3760/cma.j.cn121383-20220218-02038]

备注/Memo

备注/Memo:
基金项目:广西省自然科学基金(2017GXNSFAA198198)
更新日期/Last Update: 2020-09-20